ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,667.56
0.08%
Dow Jones
41,985.35
0.08%
US Dollar vs MXN
20.2392
0.00%
Brent Oil
71.775
0.00%
Bitcoin
84,312.54
0.56%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Alemania
  5. TG

  6. Kimberly Clark (KMY) Cotización

Kimberly Clark

Kimberly Clark (KMY)

TG
128.10
-0.04
(-0.03%)
Cerrado 23 Marzo 3:00PM
Realtime Data
Gráfico avanzado
Rendering Error

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
128.10
Postura de Compra
127.70
Postura de Venta
128.48
Volume Operado de la Acción
254
127.08 Rango del Día 129.58
114.05 Rango de 52 semanas 139.10
Capitalización de Mercado [m]
42.489B
Precio Anterior
128.14
Precio de Apertura
127.92
Hora
2
@
127.08
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
580
Acciones en circulación
331,684,601
Rendimiento del Dividendo
4.28%
Ratio Precio/Utilidad
18.07
Beneficio por acción (BPA)
7.67
turnover
20.55B
Beneficio neto
2.55B

Acerca de Kimberly Clark

Sector
Convrt Paper,paperbd Pds,nec
Industria
Convrt Paper,paperbd Pds,nec
Sitio web
www.kimberly-clark.com
Sede
Wilmington, Delaware, USA
Fundado
-
Kimberly Clark is listed in the Convrt Paper,paperbd Pds sector of the Tradegate (DE) with ticker KMY. The last closing price for Kimberly Clark was 128.14 €. Over the last year, Kimberly Clark shares have traded in a share price range of 114.05 € to 139.10 €.

Kimberly Clark currently has 331,684,601 shares in issue. The market capitalisation of Kimberly Clark is 42.50 € billion. Kimberly Clark has a price to earnings ratio (PE ratio) of 18.07.

KMY Últimas noticias

Más noticias
No hay noticias para mostrar aún.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-1.2-0.92807424594129.3129.58127.08559127.93869099DE
4-4-3.02800908403132.1139.1127.08638132.84783827DE
120.020.0156152404747128.08139.1120.82580127.74711647DE
260.920.723384179902127.18139.1120.82515127.80746585DE
5214.0512.3191582639114.05139.1114.05540126.7952408DE
15618.4516.8262653899109.65139.1107.6377121.23710267DE
26017.5815.9066232356110.52139.1106.5262120.49275384DE

KMY - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Kimberly Clark?
El precio actual de las acciones de Kimberly Clark es 128.10 €
¿Cuántas acciones de Kimberly Clark están en circulación?
Kimberly Clark tiene 331,684,601 acciones en circulación
¿Cuál es la capitalización de mercado de Kimberly Clark?
La capitalización de mercado de Kimberly Clark es EUR 42.5B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Kimberly Clark?
Kimberly Clark ha negociado en un rango de 114.05 € a 139.10 € durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Kimberly Clark?
El ratio precio/beneficio de Kimberly Clark es 18.07
¿Cuál es el ratio de efectivo a ventas de Kimberly Clark?
El ratio de efectivo a ventas de Kimberly Clark es 2.24
¿Cuál es la moneda de reporte de Kimberly Clark?
Kimberly Clark presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Kimberly Clark?
El último ingresos anual de Kimberly Clark es USD 20.55B
¿Cuál es el último beneficio anual de Kimberly Clark?
El último beneficio anual de Kimberly Clark es USD 2.55B
¿Cuál es la dirección registrada de Kimberly Clark?
La dirección registrada de Kimberly Clark es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Kimberly Clark?
La dirección del sitio web de Kimberly Clark es www.kimberly-clark.com
¿En qué sector industrial opera Kimberly Clark?
Kimberly Clark opera en el sector CONVRT PAPER,PAPERBD PDS,NEC

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
AMIMedondo Holding AG
0.498 €
(91.54%)
180
R1EAEV Resources Ltd
0.0036 €
(63.64%)
70k
GTYGateway Real Estate AG
0.65 €
(44.44%)
13.3k
51JVivoPower International PLC
1.14 €
(43.40%)
29.04k
9YZCredissential Inc
0.019 €
(31.03%)
19.5k
E3O1Nexoptic Technology Corp
0.006 €
(-29.41%)
1.99k
PA8Paion AG
0.0142 €
(-28.28%)
75
PNYPine Technology Holdings Ltd
0.004 €
(-27.27%)
20k
L7C2Windfall Geotek Inc
0.0085 €
(-26.09%)
71.58k
GAG0GORE German Office Real Estate AG
0.10 €
(-25.93%)
4k
DEZDeutz AG
7.33 €
(19.19%)
4.37M
D7GNel ASA
0.2585 €
(-1.11%)
3.29M
DMLSayona Mining Limited
0.0119 €
(-4.03%)
2.72M
LLDLloyds Banking Group PLC
0.86 €
(-2.27%)
2.23M
0QJHexagon Purus ASA
0.1296 €
(-17.66%)
1.84M

KMY Finanzas

Finanzas
Rendering Error

Discusión

Ver feed completo
$2.00 or no deal $2.00 or no deal 2 minutos hace
You'd have to be the dumbest motha phuckin CEO on the PLANET if you tried to sell Elite right now or ANY time soon.

❌️ Still on the OTC
❌️ All the BE studies failed last year
❌️ Generic OxyContin uncertainty
❌️ Vyvanse JUST launched
❌️ Mikah owns half the A
ELTP
kazzy kazzy 5 minutos hace
Looks like Expansion 3 is a Texas DWP project @ 8MTPA. It's written on the new homepage:

Expansion and growth potential of up to 16 MTPA with the Avocet LNG project and a Texas DWP project

https://delfinmidstream.com/
TGLO
fregata fregata 6 minutos hace
kthomp19 is paid common lunatic hater with LOW IQ LEVEL ,HAVING MENTAL RETARDATION .
FNMA
david444 david444 8 minutos hace
$TMSH 1.8B OS trip2 new CEO AI stock Pioneering human centric technologies. 5 entities in AI, mental wellness, performance analytics, sports/entertainment merging into $TMSH.

Acquired Mindwell Solutions Group LLC through new CEO Michael Berman. Here is Michael Berman's bio from Mindw
TMSH
$2.00 or no deal $2.00 or no deal 11 minutos hace
Nice...

Repeal the Mikah Tax -- To be paid by all shareholders at buyout
1. Cost of Second Tier Suitors
2. Cost of Secret Side Deal with Hakim
3. Cost of Mikah litigation
4. Cost of remaining OTC
ELTP
$2.00 or no deal $2.00 or no deal 11 minutos hace
All the BE studies failed last year.

Nasrat lied to us when said QUOTE "At least two ANDA's will be filed in 2024".

And he said one of these was the CNS product (Concerta).

I’d like Elite to expand their portfolio. The best way is having ANDA’s approved.
ELTP
$2.00 or no deal $2.00 or no deal 15 minutos hace
You mean Kirko...

Nasrat was all in years ago and deserves both the credit and the rewards for making this company a force in the generic drug field.
ELTP
Truenorth2016 Truenorth2016 22 minutos hace
Also Stervc, GCAN CEO Aitan keeps emphasizing in Core Gaming Pr's and the merger video, this:

"Core Gaming has developed cutting edge AI tools using text, language, image and video models to achieve a 50% boost in content production, reducing production time by over 40%, and significa
GCAN
Peter J Peter J 24 minutos hace
Well...HELLO mr fung derf...

LET'S WELCOME A NEW MEMBER TO THE ALTRUIST GANG... 🤣

However, my answer is, I don't care about what is posted if its not intended to hurt others
ERHE
Polymer Paul Polymer Paul 25 minutos hace
This is good.... So you now know that when Yves says 18-24 months for results... He means 18-24 months !!! Long time off that Belgium ... Very long time in the stock world. Good luck with that
LWLG
$2.00 or no deal $2.00 or no deal 25 minutos hace
EVERYONE CARES about what happened 10 years ago!

NO ONE CARES about what happened 10 years ago!
ELTP
$2.00 or no deal $2.00 or no deal 26 minutos hace
Agreed!

Hakim is a miserable failure when it comes to fulfilling his fiduciary duty to Elite shareholders.
ELTP
Peter J Peter J 27 minutos hace
Still posting, mr. 6503 posts? While having no financial interest here... 🤣
https://investorshub.advfn.com/boards/profileb.aspx?user=44043
ERHE
$2.00 or no deal $2.00 or no deal 27 minutos hace
He's been horrible.

Nasrat has been an amazing CEO for investors that have held their shares.
ELTP
Wayne R Wayne R 29 minutos hace
Last month was last month, this is this month and they just voted for another this month.

Sure, I know it is hard to keep track....
MULN
BDEZ BDEZ 37 minutos hace
LBJ Talks About Shooting Methamphetamine with Jackie Kennedy in Newly Released Presidential Phone Call

https://x.com/RealAlexJones/status/1903544281098330461
Truenorth2016 Truenorth2016 40 minutos hace
In Our Face Stervc!! NVDA and Core Gaming has the same tech and this is why GCAN CEO Aitan Zacharin keep saying his company is going to soon be the Number One "AI Gaming" Company in the world...... AITAN has something up his sleeve.....he knows he has tech that no one else has or has an edge on othe
GCAN NVDA
SkeBallLarry SkeBallLarry 40 minutos hace
Now there's a good one, Trin .. !!!
Investor2014 Investor2014 44 minutos hace
In the current context and considering Missling is from Europe, where approval is sought from EMA. Anavex have run only one tiny adult Rett trial in the U.S., all other trials have been run in countries collaborating with Europe. Considering all this - the Anavex HQ may not be in NYC or anywhere clo
AVXL
BDEZ BDEZ 50 minutos hace
Foreman was a prominent promoter of the jab. Even doing paid commercials

https://x.com/RealAlexJones/status/1903397708368404556
Flexplate Flexplate 55 minutos hace
Live Update At 09:18:06 EST: On Friday, March 21, 2025 TransCode Therapeutics Inc. stock [NASDAQ: RNAZ] is trending up by 34.42%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

TransCode Therapeutics received a nod to proc
RNAZ
cleanerworldwehope cleanerworldwehope 59 minutos hace
Scancell announces further positive data from the ongoing SCOPE trial of SCIB1 with double CPIs for Advanced
Melanoma
80% Progression Free Survival in 25 patients at 6 months
20% (5) patients have shown a complete response following treatment
Disease Control Rate of 84% a
MRNA

Su Consulta Reciente

TG
KMY
Kimberly Clark
Delayed Upgrade Clock
ADVFN Logo
México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios